10 Best Dividend Paying Drug Manufacturing Stocks (2024)

Thebest dividend paying stocks from the major drug manufacturing industryoriginally published at "long-term-investments.blogspot.com".Thehealthcare sector is another great investment field for me. I mainly like itbecause of the ongoing aging population. The older people are, the morehealthcare they need. The big problem is that most of the people don’t havesaved enough money to finance all their health services and products - Thegovernment must care for it and makes it via health care plans, insurance,hospitals, education and so on. This means also a state related dependence forthe investor.

Oneof the best yielding industries within the healthcare sector is the major drugmanufacturing industry. The average yield amounts to 3.85 percent and the P/E’son a level of 18.0. The industry has exactly 10 dividend stocks and is stillthe biggest investment field followed by a ten times smaller Biotechnologyindustry. I believe that the biotech's will perform better and catch up to theleading industry unless the old drug companies will not overtake them. Thereason is simple: They are more innovative.

However,below is a small list of the best dividend paying major drug manufacturingstocks. From 10 stocks have seven with a buy or even better rating. Despite thegreat predictions of decreasing sales and earnings due to patent losses, growthis still forecasted for the most of the drug dividend stocks.

Here are my favorite stocks:

If you like to receive more news and regular dividendupdates, you should subscribe to my free E-Mail list.Alternative, you can follow meonFacebookorTwitter.

GlaxoSmithKline (NYSE:GSK) has a market capitalization of $108.42 billion. The company employs 97,389 people, generates revenue of $39.741 billion and has a net income of $7.133 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $11.831 billion. The EBITDA margin is 29.77 percent (the operating margin is 27.97 percent and the net profit margin 17.95 percent).

Financial Analysis:The total debt represents 44.13 percent of the company’s assets and the total debt in relation to the equity amounts to 315.01 percent. Due to the financial situation, a return on equity of 65.96 percent was realized. Twelve trailing months earnings per share reached a value of $2.73. Last fiscal year, the company paid $2.23 in the form of dividends to shareholders.

Market Valuation:Here are the price ratios of the company: The P/E ratio is 16.22, the P/S ratio is 2.74 and the P/B ratio is finally 12.41. The dividend yield amounts to 5.30 percent and the beta ratio has a value of 0.63.

Long-Term Stock History Chart Of GlaxoSmithKline (GSK)

Long-Term Dividends History of GlaxoSmithKline (GSK)

Long-Term Dividend Yield History of GlaxoSmithKline (GSK)

Sanofi (NYSE:SNY) has a market capitalization of $124.12 billion. The company employs 113,719 people, generates revenue of $45.771 billion and has a net income of $6.350 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $13.360 billion. The EBITDA margin is 29.19 percent (the operating margin is 16.18 percent and the net profit margin 13.87 percent).

Financial Analysis:The total debt represents 15.41 percent of the company’s assets and the total debt in relation to the equity amounts to 27.46 percent. Due to the financial situation, a return on equity of 10.42 percent was realized. Twelve trailing months earnings per share reached a value of $2.95. Last fiscal year, the company paid $1.73 in the form of dividends to shareholders.

Market Valuation:Here are the price ratios of the company: The P/E ratio is 15.94, the P/S ratio is 2.76 and the P/B ratio is finally 1.70. The dividend yield amounts to 3.94 percent and the beta ratio has a value of 0.90.

Long-Term Stock History Chart Of Sanofi (SNY)

Long-Term Dividends History of Sanofi (SNY)

Long-Term Dividend Yield History of Sanofi (SNY)

Bristol Myers Squibb (NYSE:BMY) has a market capitalization of $60.83 billion. The company employs 28,000 people, generates revenue of $17.621 billion and has a net income of $2.501 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $3.222 billion. The EBITDA margin is 18.28 percent (the operating margin is 13.28 percent and the net profit margin 14.19 percent).

Financial Analysis:The total debt represents 20.60 percent of the company’s assets and the total debt in relation to the equity amounts to 54.28 percent. Due to the financial situation, a return on equity of 13.25 percent was realized. Twelve trailing months earnings per share reached a value of $1.15. Last fiscal year, the company paid $1.37 in the form of dividends to shareholders.

Market Valuation:Here are the price ratios of the company: The P/E ratio is 32.22, the P/S ratio is 3.45 and the P/B ratio is finally 4.45. The dividend yield amounts to 3.77 percent and the beta ratio has a value of 0.42.

Long-Term Stock History Chart Of Bristol Myers Squibb (BMY)

Long-Term Dividends History of Bristol Myers Squibb (BMY)

Long-Term Dividend Yield History of Bristol Myers Squibb (BMY)

Take a closer look at the full list of the best dividend paying drug stocks. The average P/E ratio amounts to 18.66and forward P/E ratio is 13.35. The dividend yield has a value of 4.27 percent.Price to book ratio is 4.21 and price to sales ratio 2.84. The operating marginamounts to 20.82 percent and the beta ratio is 0.65. Stocks from the list havean average debt to equity ratio of 2.56.

Here is the full table withsome fundamentals (TTM):

Best Yielding Drug Manufacturing Stocks (Click to enlarge)

If you like this list, please give us a Facebook Like, make a tweet or post a comment below!

Related stockticker symbols:

AZN, GSK, ABBV,MRK, BMY, NVS, SNY, LLY, PFE, JNJ, ETE

Selected Articles:

*I am long AZN. I receiveno compensation to write about these specific stocks, sector or theme. I don'tplan to increase or decrease positions or obligations within the next 72 hours.

For the other stocks: Ihave no positions in any stocks mentioned, and no plans to initiate anypositions within the next 72 hours. I receive no compensation to write aboutany specific stock, sector or theme.